Related references
Note: Only part of the references are listed.Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
Andrew D. Zelenetz et al.
LANCET ONCOLOGY (2017)
Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial
Jeffrey A. Jones et al.
LANCET HAEMATOLOGY (2017)
Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study
Anat Gafter-Gvili et al.
LEUKEMIA & LYMPHOMA (2016)
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib
Inhye E. Ahn et al.
BLOOD (2016)
The impact of migration on tuberculosis epidemiology and control in high-income countries: a review
Manish Pareek et al.
BMC MEDICINE (2016)
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
Maria Winqvist et al.
HAEMATOLOGICA (2016)
DISSEMINATED HERPES ZOSTER IN CHRONIC LYMPHOCYTIC LEUKEMIA
Elizabeth Sutton et al.
JOURNAL OF EMERGENCY MEDICINE (2016)
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
Stephan Stilgenbauer et al.
LANCET ONCOLOGY (2016)
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
Asher Chanan-Khan et al.
LANCET ONCOLOGY (2016)
Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death
Michael Asger Andersen et al.
LEUKEMIA & LYMPHOMA (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
Maria Winqvist et al.
HAEMATOLOGICA (2016)
Acquired epidermodysplasia verruciformis, a new opportunistic infection related to bendamustine
P. Cougoul et al.
ANNALS OF HEMATOLOGY (2015)
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
B. Eichhorst et al.
ANNALS OF ONCOLOGY (2015)
Restoring Ikaros's wings to solve a leukemia maze
Camille Lobry
BLOOD (2015)
Perturbation of the normal immune system in patients with CLL
Francesco Forconi et al.
BLOOD (2015)
A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
Susan M. O'Brien et al.
BLOOD (2015)
Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
John C. Byrd et al.
BLOOD (2015)
Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes
Sameer A. Parikh et al.
CANCER (2015)
Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough?
Jesse Civan et al.
EXPERT OPINION ON DRUG SAFETY (2015)
Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy
Andrea Visentin et al.
HAEMATOLOGICA (2015)
Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages
Mercedes Borge et al.
HAEMATOLOGICA (2015)
Management of adverse events associated with idelalisib treatment: expert panel opinion
Steven E. Coutre et al.
LEUKEMIA & LYMPHOMA (2015)
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
J. A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development
E. N. Smith et al.
BLOOD CANCER JOURNAL (2015)
Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy
Andrea Visentin et al.
HAEMATOLOGICA (2015)
Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages
Mercedes Borge et al.
HAEMATOLOGICA (2015)
Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
G. Maschmeyer et al.
ANNALS OF ONCOLOGY (2015)
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy
Fabio Da Roit et al.
HAEMATOLOGICA (2015)
Pneumocystis jiroveci prophylaxis in patients undergoing Bendamustine treatment: the need for a standardized protocol
Tarig Mohammed Abkur et al.
CLINICAL CASE REPORTS (2015)
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
Jennifer R. Brown et al.
BLOOD (2014)
Immunoglobulin deficiency in patients with Streptococcus pneumoniae or Haemophilus influenzae invasive infections
Martin Martinot et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2014)
Antibody Deficiency Secondary to Chronic Lymphocytic Leukemia: Should Patients be Treated with Prophylactic Replacement Immunoglobulin?
Fatima Dhalla et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2014)
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
S. Neumann et al.
ANNALS OF HEMATOLOGY (2013)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Increased Frequency of CD8+ and CD4+ Regulatory T Cells in Chronic Lymphocytic Leukemia: Association with Disease Progression
Farhad Jadidi-Niaragh et al.
CANCER INVESTIGATION (2013)
Visceral Varicella in a Patient With Chronic Lymphocytic Leukemia Treated With Fludarabine: A Case Report
Daniel E. Freedberg et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections
Carla Casulo et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Which patients should be tested for viruses on bronchoalveolar lavage fluid?
S. Jouneau et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2013)
Tumor-induced host immunosuppression: Special focus on CLL
Christine E. Cutucache
INTERNATIONAL IMMUNOPHARMACOLOGY (2013)
Triggers for driving treatment of at-risk patients with invasive fungal disease
Lubos Drgona et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function
DJ DiLillo et al.
LEUKEMIA (2013)
Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia
Jane A. Freeman et al.
LEUKEMIA & LYMPHOMA (2013)
Viral infections and their management in patients with chronic lymphocytic leukemia
Thomas Melchardt et al.
LEUKEMIA & LYMPHOMA (2013)
Bendamustine in Indolent Non-Hodgkin's Lymphoma: A Practice Guide for Patient Management
Wolfram Brugger et al.
ONCOLOGIST (2013)
Neutropenia after rituximab treatment: new insights on a late complication
Ofir Wolach et al.
CURRENT OPINION IN HEMATOLOGY (2012)
Insect-bite-like reaction in patients with chronic lymphocytic leukemia: a study from the Israeli Chronic Lymphocytic Leukemia Study Group
Osnat Bairey et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia
Lukas Smolej
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Bendamustine for treatment of chronic lymphocytic leukemia
Julie Elizabeth Chang et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine
Yutaka Tsutsumi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2012)
Hepatitis B reactivation despite entecavir prophylaxis in a patient with chronic lymphocytic leukaemia receiving bendamustine
Angela Rago et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
George Papatheodoridis et al.
JOURNAL OF HEPATOLOGY (2012)
Infectious Complications in Chronic Lymphocytic Leukemia
Annamaria Nosari
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2012)
B-cell receptor signaling in chronic lymphocytic leukemia
Freda K. Stevenson et al.
BLOOD (2011)
Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells
K. P. Piper et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2011)
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
M. S. Aapro et al.
EUROPEAN JOURNAL OF CANCER (2011)
Does rituximab increase the incidence of infectious complications? A narrative review
Theodoros Kelesidis et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2011)
Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial
Thomas Elter et al.
LANCET ONCOLOGY (2011)
Reactivation of hepatitis B virus following bendamustine-containing chemotherapy in a patient with multiple myeloma
Umit Tapan et al.
LEUKEMIA & LYMPHOMA (2011)
Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma
Stephanie J. Carter et al.
LEUKEMIA RESEARCH (2011)
Azithromycin for Prevention of Exacerbations of COPD
Richard K. Albert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia
Jan A. Burger
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2011)
Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches
Vicki A. Morrison
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2010)
Predictors of infection in chronic lymphocytic leukaemia (CLL)
H. GRIFFITHS et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Bendamustine Produces Durable Responses With an Acceptable Safety Profile in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma
Bruce D. Cheson et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2010)
Functional abnormalities in granulocytes predict susceptibility to bacterial infections in chronic lymphocytic leukaemia
M. Itälä et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Severe immunodeficiency in patients treated with fludarabine monophosphate
P. W. Wijermans et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Infection as a comorbidity of COPD
S. Sethi
EUROPEAN RESPIRATORY JOURNAL (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy
L. Ysebaert et al.
LEUKEMIA (2010)
Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia
Ana P. Gonzalez-Rodriguez et al.
LEUKEMIA & LYMPHOMA (2010)
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Kenneth R. Carson et al.
BLOOD (2009)
Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia
Lesley A. Anderson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Pathogenesis, Diagnosis, and Management of Primary Antibody Deficiencies and Infections
Ari J. Fried et al.
CLINICAL MICROBIOLOGY REVIEWS (2009)
Chronic Hepatitis B: Update 2009
Anna S. F. Lok et al.
HEPATOLOGY (2009)
Monoclonal anti body-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project
Kenneth R. Carson et al.
LANCET ONCOLOGY (2009)
Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis
Pia Raanani et al.
LEUKEMIA & LYMPHOMA (2009)
Infectious Complications in Patients With Chronic Lymphocytic Leukemia: Pathogenesis, Spectrum of Infection, and Approaches to Prophylaxis
Vicki A. Morrison
CLINICAL LYMPHOMA & MYELOMA (2009)
The Role of Tec Family Kinases in Mononuclear Phagocytes
Afitap Derya Koepruelue et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2009)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
The immunodeficiency of chronic lymphocytic leukaemia
A. D. Hamblin et al.
BRITISH MEDICAL BULLETIN (2008)
Epidemiology of acute infections among patients with chronic kidney disease
Lorien S. Dalrymple et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura
Roberto Stasi et al.
BLOOD (2007)
Rituximab-related viral infections in lymphoma patients
Sercan Aksoy et al.
LEUKEMIA & LYMPHOMA (2007)
Cutting edge:: The phosphoinositide 3-kinase p110δ is critical for the function of CD4+CD25+Foxp3+ regulatory T cells
Daniel T. Patton et al.
JOURNAL OF IMMUNOLOGY (2006)
The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia
Sebastian Francis et al.
CANCER (2006)
Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzamab
Susan M. O'Brien et al.
CLINICAL LYMPHOMA & MYELOMA (2006)
Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO)
M. Sandherr et al.
ANNALS OF ONCOLOGY (2006)
Infectious complications of chronic lymphocytic leukemia
PD Wadhwa et al.
SEMINARS IN ONCOLOGY (2006)
Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab
KA Thursky et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia:: Results of a phase II trial
T Elter et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Serious infections in elderly patients with diabetes mellitus
S Rajagopalan
CLINICAL INFECTIOUS DISEASES (2005)
Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia
J Lundin et al.
LEUKEMIA (2004)
Pulmonary complications in chronic lymphocytic leukemia
S Ahmed et al.
CANCER (2003)
Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia
M Hensel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Abnormal T-cell function in B-cell chronic lymphocytic leukaemia
S Scrivener et al.
LEUKEMIA & LYMPHOMA (2003)
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
MJ Keating et al.
BLOOD (2002)
Humoral immunodeficiency in chronic lymphocytic leukemia: Role of CD95/CD95L in tumoral damage and escape
A Sampalo et al.
LEUKEMIA & LYMPHOMA (2002)
Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma - Implications for clinical trials in this patient population
JG Perkins et al.
CANCER (2002)
Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011
VA Morrison et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Hepatitis B virus core antigen binds and activates naive human B cells in vivo:: Studies with a human PBL-NOD/SCID mouse model
TH Cao et al.
JOURNAL OF VIROLOGY (2001)
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome
L Fayad et al.
BLOOD (2001)
Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin
JF Westphal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2000)
Share Paper
